Oral semaglutide does not slow the progression of Alzheimer's disease, according to a trial Oral semaglutide is not effective in slowing the progression of the disease in patients with mild Alzheimers disease, according to the findings of the first large-scale, randomised phase 3 clinical trials published in The Lancet
The SmPC notes an interaction with increased thyroxine exposure, so discuss the optimal timing of both medications with your GP, as they may need to be spaced further apart and thyroid function monitoring may be required
Sometimes we had to ask support directly
The exact starting dose and the final dosage will depend on the patient, their reaction to the medication, and several other factors
Oshman also notes that the Bridge program doesnt require patients to be seen in person by the prescriber before receiving the prescription, nor that the prescriber have any relationship with the patient or experience prescribing under the Medicare system before prescribing the GLP-1 to them
95% CI, 0.68-1), low-range prediabetes (HR = 0.77